# US Kidney Biopsy Market > US Kidney Biopsy Market Research Report By End-User (Hospitals & Clinics, Urology Centers, Tertiary Care Centers, Others), By Indication (Kidney Failure, Kidney Transplant, Hematuria, Proteinuria) and By Type (Percutaneous Biopsy, Surgical Biopsy) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.57% - **2024:** $ 693 Million - **2025:** $ 724.67 Million - **2035:** $ 1,133.19 Million - **Key Players:** Fresenius Medical Care (DE), Baxter International (US), Thermo Fisher Scientific (US), Abbott Laboratories (US), Siemens Healthineers (DE), Roche Diagnostics (CH), Philips Healthcare (NL), Medtronic (US) **Report ID:** MRFR/MED/17855-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-kidney-biopsy-market-19402 --- ## Market Summary ## **US Kidney Biopsy Market Overview** As per MRFR analysis, the US Kidney Biopsy Market Size was estimated at 616 (USD Million) in 2023. The US Kidney Biopsy Market Industry is expected to grow from 646.8(USD Million) in 2024 to 1,059.76 (USD Million) by 2035. The US Kidney Biopsy Market CAGR (growth rate) is expected to be around 4.591% during the forecast period (2025 - 2035). ### **Key US Kidney Biopsy Market Trends Highlighted** The US Kidney Biopsy Market is experiencing several notable trends driven by advancements in technology and an increasing prevalence of chronic kidney diseases. One of the key market drivers is the rising incidence of kidney-related disorders, prompting healthcare providers to turn to biopsy procedures for accurate diagnosis and effective treatment options. As awareness regarding kidney health continues to grow, there is a notable push for early detection of kidney diseases, further emphasizing the role of biopsies.  Additionally, the integration of advanced imaging techniques and needle biopsy methods enhances the safety and accuracy of procedures, leading to more favorable patient outcomes.Opportunities for growth in the US market can be explored through the development of innovative biopsy devices and techniques, including minimally invasive options that reduce recovery time and complications associated with traditional methods. Further advancements in precision medicine offer potential for personalized treatment plans, which can greatly influence patient care and improve chronic disease management.  Recent trends indicate a shift towards outpatient procedures for kidney biopsies, facilitated by advancements in imaging modalities and growing preferences for less invasive treatments. Furthermore, collaborations among healthcare providers, academic institutions, and research organizations are increasingly focusing on refining biopsy protocols and improving patient outcomes.With an emphasis on dietary education and lifestyle modifications alongside medical interventions, the US healthcare system is also prioritizing preventive approaches to kidney health, which might indirectly increase the demand for kidney biopsy procedures in the long term. These trends collectively point towards a dynamic and evolving landscape in the US Kidney Biopsy Market, with significant implications for healthcare providers and patients alike. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Kidney Biopsy Market Drivers** ### **Rising Prevalence of Kidney Diseases** The increasing incidence of kidney diseases in the United States significantly drives the US Kidney Biopsy Market Industry. According to the Centers for Disease Control and Prevention, approximately 37 million adults in the US are estimated to have chronic kidney disease (CKD), which is about 15% of the adult population. As renal diseases continue to rise, the need for accurate diagnosis requiring kidney biopsies is also expected to increase. The National Kidney Foundation and other organizations advocate for earlier detection and intervention strategies, promoting kidney biopsies as a crucial tool in managing CKD and other renal dysfunctions.This growing patient demographic presents a compelling opportunity for advancements in biopsy methodologies and technologies, further solidifying the importance of biopsies in healthcare settings across the nation. ### **Technological Advancements in Biopsy Techniques** Technological advancements in kidney biopsy techniques are fueling growth in the US Kidney Biopsy Market Industry. Innovations such as ultrasound-guided biopsies and needle technologies have improved the accuracy and safety of biopsy procedures. The introduction of automated devices and imaging techniques has been reported to reduce complications associated with traditional methods. The American Urological Association has highlighted that ultrasound guidance can increase the success rate of kidney biopsies by up to 90%, thereby encouraging more medical professionals to adopt these advanced techniques.As technology continues to evolve, it is expected that more healthcare facilities will integrate these innovations, enhancing patient outcomes related to kidney health. ### **Increase in the Geriatric Population** The increasing geriatric population in the United States is another significant driver for the US Kidney Biopsy Market Industry. As per the Administration for Community Living, the percentage of the population aged 65 and older is projected to reach approximately 23% by 2060. This demographic is more susceptible to various health issues, including kidney diseases, necessitating precise diagnostic techniques such as kidney biopsies. With programs like the Affordable Care Act promoting preventive care for seniors, the accessibility of kidney biopsies is likely to increase in the coming years.The growing need for effective management of kidney-related diseases in older adults positions kidney biopsies as a crucial component of the healthcare system. ## **US Kidney Biopsy Market Segment Insights** ### **Kidney Biopsy Market End-User Insights** The US Kidney Biopsy Market offers significant insights into its End-User segmentation, which primarily includes Hospitals and Clinics, Urology Centers, Tertiary Care Centers, and other specialized facilities. Hospitals and Clinics generally account for a major share of the kidney biopsy procedures performed, driven by their comprehensive facilities and access to advanced diagnostic technologies. They are integral in managing patient care, particularly in urban settings where the demand for early detection of kidney-related disorders is crucial.Urology Centers focus specifically on urological conditions and play a vital role in kidney biopsies by offering specialized expertise, thus ensuring accurate diagnoses and improved patient outcomes. These centers are increasingly becoming vital as more patients seek targeted care from specialists.  Tertiary Care Centers, known for their advanced medical technologies and specialized treatment protocols, are significant players in the market as they often handle complex cases requiring expert evaluation. Other facilities comprise outpatient clinics and diagnostic centers, which provide alternative options for patients seeking kidney biopsies, contributing to the overall accessibility of these services.This diverse array of end-users demonstrates the multifaceted nature of the US health care landscape related to kidney biopsy, highlighting the importance of each segment in meeting growing patient demands and fulfilling the need for precise diagnosis in kidney health.  The increasing prevalence of chronic kidney diseases and advancements in biopsy techniques further enhance the importance of these facilities, creating opportunities for growth and development across all End-User categories in the market. Emphasizing the capabilities of each segment reveals how they contribute to the broader landscape of the US Kidney Biopsy Market, significantly influencing market dynamics and driving innovation in procedures and patient care. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Kidney Biopsy Market Indication Insights** The US Kidney Biopsy Market is a crucial part of the healthcare landscape, specifically concerning the management and diagnosis of various kidney-related disorders. Within this market, the Indication segment highlights significant areas such as Kidney Failure, Kidney Transplant, Hematuria, and Proteinuria, each playing a vital role in understanding and treating kidney diseases. Kidney Failure is a critical area that drives the need for biopsies due to the complexity of diagnosis and treatment decisions involved for nephrologists. Kidney Transplant cases are often accompanied by biopsy procedures to ensure optimal post-surgical outcomes and to monitor for rejection.Meanwhile, Hematuria Treatment and Proteinuria are essential indicators of kidney issues that prompt health practitioners to perform biopsies for precise assessment. The increasing incidence of these conditions, influenced by factors like diabetes and hypertension, further underscores the importance of the Indication segment. As awareness of kidney health escalates in the US, the relevance of these indications in guiding treatment strategies and enhancing patient outcomes continues to grow, ultimately propelling advancements in the US Kidney Biopsy Market. ### **Kidney Biopsy Market Type Insights** The US Kidney Biopsy Market segmentation by Type reveals critical insights into the methodologies employed for kidney diagnostics. Key segments include Percutaneous Biopsy and Surgical Biopsy, each playing a pivotal role in the overall market. Percutaneous Biopsy is increasingly favored due to its minimally invasive nature, leading to shorter recovery times and reduced patient discomfort, which resonates well with the growing patient-centric healthcare approach in the United States. On the other hand, Surgical Biopsy continues to maintain significance in complex cases where detailed tissue analysis is required, showcasing its importance in comprehensive diagnostics.The rising prevalence of kidney diseases and disorders, largely attributable to diabetes and hypertension, propels the demand for efficient biopsy techniques. Furthermore, advancements in imaging technologies enhance the precision of these procedures, bolstering market growth. Overall, the US Kidney Biopsy Market continues to evolve with a focus on improving patient outcomes and procedural efficiencies, presenting both challenges and opportunities for healthcare providers and practitioners in this critical aspect of renal health management. ## **US Kidney Biopsy Market Key Players and Competitive Insights** The US Kidney Biopsy Market is characterized by an array of sophisticated medical technologies and services aimed at enhancing the diagnosis and treatment of kidney-related ailments. This market has been experiencing considerable growth due to the increasing prevalence of chronic kidney diseases and the rising need for accurate diagnostic procedures. The competitive landscape is shaped by various key players who are innovating and expanding their product offerings to capture a larger share of this specialized market. The competitive insights reveal that companies are focusing not only on improving the accuracy and efficiency of biopsy procedures but also on enhancing patient experiences and outcomes. Advancements in imaging techniques and minimally invasive procedures are also becoming significant trends that drive competition within this sector. Exact Sciences holds a strategic position in the US Kidney Biopsy Market, focusing on developing innovative diagnostic solutions tailored to the needs of kidney disease patients. The company's strength lies in its commitment to research and development, which propels the introduction of cutting-edge technologies that facilitate non-invasive and minimally invasive biopsy procedures. Exact Sciences has garnered a reputation for reliable diagnostics, bolstered by its rigorous testing protocols and partnerships with healthcare providers. Their approach emphasizes both accuracy and patient-centered care, making them a formidable competitor in this market landscape. Exact Sciences' ability to address the growing demand for kidney diagnostics through technological advancements strengthens its position, allowing for continuous growth and expansion in the US market. Hologic is another significant player in the US Kidney Biopsy Market, known for its robust portfolio of diagnostic and imaging solutions that cater specifically to nephrology. The company has established a strong presence through its innovative products and services, which not only include advanced biopsy systems but also comprehensive imaging solutions that enhance procedural efficiency. Hologic's strengths lie in its cutting-edge technology and commitment to precision medicine, bolstering its market presence among healthcare professionals. The company has actively pursued mergers and acquisitions to expand its capabilities and reach within the kidney biopsy segment, enhancing its service offerings and market position. Their focus on addressing the specific needs of kidney disease diagnostics, coupled with a strong distribution network, further reinforces Hologic’s competitive advantage in the US market. ### **Key Companies in the US Kidney Biopsy Market Include** ### **US Kidney Biopsy Market Industry Developments** Recent developments in the US Kidney Biopsy Market reflect significant advancements and competitive dynamics among key players. Companies like Exact Sciences, Hologic, and BioRad Laboratories are actively innovating within this space, focusing on novel biomarker discovery and enhanced diagnostic techniques. The market continues to see a growing interest in minimally invasive procedures, significantly benefitting patients and healthcare providers alike. In terms of mergers and acquisitions, there has been notable activity, including Roche Diagnostics acquiring a strategic technology firm in September 2023 to bolster their diagnostic offerings in kidney-related diseases, and Laboratory Corporation of America acquiring a promising biotechnology startup in August 2023 to enhance laboratory capabilities. Over the past few years, the US Kidney Biopsy Market has also experienced increased investment, fueled by a rise in chronic kidney diseases, heightening demand for groundbreaking diagnostic solutions. Companies such as Thermo Fisher Scientific and Quest Diagnostics are expanding their portfolio to include advanced genomic analysis technologies, further driving market growth. Overall, the US Kidney Biopsy Market showcases robust activity and innovation, positioning itself for significant future developments in the healthcare industry. ## **US Kidney Biopsy Market Segmentation Insights** ### **Kidney Biopsy Market End-User Outlook** ### **Kidney Biopsy Market Indication Outlook** ### **Kidney Biopsy Market Type Outlook** ## Market Drivers ### Advancements in Biopsy Techniques Advancements in biopsy techniques are driving growth in the kidney biopsy market.. Innovations such as ultrasound-guided biopsies and core needle biopsies have enhanced the safety and efficacy of the procedure. These techniques reduce complications and improve patient comfort, making kidney biopsies more accessible. As a result, healthcare providers are increasingly adopting these advanced methods, contributing to the market's expansion. The introduction of robotic-assisted biopsy systems may further revolutionize the field, potentially increasing the precision of tissue sampling. By 2025, the kidney biopsy market is projected to reach $1.5 billion, driven by these technological advancements that enhance procedural outcomes and patient satisfaction. ### Growing Investment in Renal Research The kidney biopsy market is benefiting from growing investment in renal research. Increased funding from both public and private sectors is facilitating the exploration of novel diagnostic and therapeutic approaches for kidney diseases. Research initiatives are focusing on understanding the pathophysiology of renal disorders, which often necessitate biopsy for accurate diagnosis. This influx of investment is likely to stimulate innovation in biopsy techniques and related technologies, thereby expanding the market. By 2025, the kidney biopsy market is expected to reach approximately $1.5 billion, reflecting the positive impact of research funding on the development of advanced diagnostic tools and treatment modalities. ### Increasing Demand for Diagnostic Accuracy The kidney biopsy market is experiencing a notable surge in demand for diagnostic accuracy. As healthcare providers strive to enhance patient outcomes, the need for precise diagnostic tools becomes paramount. Kidney biopsies are essential for diagnosing various renal conditions, including glomerulonephritis and kidney tumors. The market is projected to grow as advancements in imaging techniques and histopathological analysis improve the accuracy of biopsy results. In 2025, the market is expected to reach approximately $1.5 billion, reflecting a compound annual growth rate (CAGR) of around 6%. This growth is driven by the increasing emphasis on personalized medicine, where accurate diagnosis is crucial for tailoring treatment plans. Consequently, the kidney biopsy market is likely to expand as healthcare systems prioritize diagnostic precision. ### Rising Prevalence of Chronic Kidney Disease The kidney biopsy market is significantly influenced by the rising prevalence of chronic kidney disease (CKD) in the United States. According to the Centers for Disease Control and Prevention (CDC), approximately 15% of adults in the U.S. are estimated to have CKD, a condition that often necessitates biopsy for accurate diagnosis and management. This increasing incidence of CKD is likely to drive demand for kidney biopsies, as healthcare providers seek to identify the underlying causes of renal impairment. The market is projected to grow in response to this trend, with an anticipated value of $1.5 billion by 2025. As awareness of CKD rises, coupled with improved screening and diagnostic protocols, the kidney biopsy market is expected to expand, reflecting the urgent need for effective management strategies. ### Enhanced Awareness and Education on Kidney Health The kidney biopsy market is experiencing growth due to enhanced awareness and education regarding kidney health. Public health campaigns and educational initiatives are increasing knowledge about kidney diseases and the importance of early diagnosis. As individuals become more informed about the risks associated with kidney conditions, there is a corresponding rise in demand for diagnostic procedures, including biopsies. This trend is likely to drive the kidney biopsy market, as healthcare providers respond to the growing need for accurate diagnostic tools. By 2025, the market is projected to reach $1.5 billion, reflecting the influence of increased awareness on healthcare-seeking behavior and the subsequent demand for kidney biopsies. ## Future Outlook The [Kidney Biopsy Market](https://www.marketresearchfuture.com/reports/kidney-biopsy-market-5309) is projected to grow at a 4.57% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of kidney diseases, and rising demand for minimally invasive procedures. **New opportunities:** - Development of AI-driven diagnostic tools for enhanced accuracy in biopsy analysis. - Expansion of telemedicine services for remote biopsy consultations and follow-ups. - Investment in training programs for nephrologists to improve biopsy techniques and patient outcomes. By 2035, the kidney biopsy market is expected to achieve substantial growth, reflecting evolving healthcare needs. ## Segment Insights ### By End-User: Hospitals & Clinics (Largest) vs. Urology Centers (Fastest-Growing) In the US kidney biopsy market, the segmentation by end-user reveals that Hospitals & Clinics hold the largest share, reflecting their critical role in providing essential medical services. This segment benefits from strong patient inflow, advanced technologies, and a comprehensive range of services, making them a preferred choice for kidney biopsies. Urology Centers, while smaller in market share compared to Hospitals & Clinics, are rapidly gaining traction as specialized facilities that cater specifically to urological health, leading to an increase in their overall share. Growth trends indicate a robust increase in both segments driven by various factors including technological advancements, increasing incidence of kidney diseases, and a focus on specialized care. As hospitals continue to integrate advanced imaging and biopsy techniques, they enhance patient outcomes, thereby solidifying their dominant position. In contrast, Urology Centers are experiencing swift growth, attributed to the rising demand for specialized treatments and the convenience they offer for patients seeking focused care in kidney-related ailments. Hospitals & Clinics (Dominant) vs. Urology Centers (Emerging) Hospitals & Clinics serve as a dominant force within the US kidney biopsy market due to their extensive infrastructure and wide-ranging clinical capabilities. These facilities are equipped with advanced diagnostic tools and experienced medical personnel, ensuring high-quality patient care and facilitating a streamlined biopsy process. Conversely, Urology Centers are emerging as vital players in this landscape, catering specifically to urologic conditions with a focus on personalized patient experiences. Their specialized services and dedicated approach are attracting more patients, contributing to their rapid growth in the market. The differentiation in services, with Hospitals & Clinics providing comprehensive care and Urology Centers emphasizing specialization, highlights the diverse needs of patients and how these segments are evolving to meet those demands. ### By Indication: Kidney Failure (Largest) vs. Kidney Transplant (Fastest-Growing) In the US kidney biopsy market, the segment values are distributed as follows: Kidney Failure holds the largest share due to its prevalence among patients requiring frequent monitoring and intervention. This segment significantly outpaces other indications, such as Hematuria and Proteinuria, which represent smaller portions of the market. The focus on early diagnosis and treatment of kidney-related issues has bolstered this segment's dominance and visibility among healthcare providers. Recent trends indicate that the Kidney Transplant segment is the fastest-growing area within the market. Factors driving this growth include advancements in transplant technology and increased awareness regarding organ donation. As the demand for kidney transplants rises due to growing kidney disease prevalence, the emphasis on effective diagnostic biopsies in this segment is likely to increase, further propelling its market position. Kidney Failure (Dominant) vs. Hematuria (Emerging) Kidney Failure remains the dominant segment within the US kidney biopsy market, characterized by a high volume of procedures driven by the significant number of individuals suffering from chronic kidney diseases. This segment's visibility in clinical settings, combined with a well-established treatment protocol, ensures a steady demand for biopsy procedures. On the other hand, Hematuria is emerging as an important segment, reflecting an increase in diagnoses related to blood in urine, which may signal underlying renal issues. While still smaller in terms of market share when compared to Kidney Failure, the growing awareness and advancements in diagnostic tools are contributing to Hematuria's rise, indicating a shift in focus within the nephrology field. ### By Type: Percutaneous Biopsy (Largest) vs. Surgical Biopsy (Fastest-Growing) The US kidney biopsy market is primarily driven by percutaneous biopsy, which commands a substantial share due to its minimally invasive nature and lower complication rates. This method has gained traction among healthcare professionals, leading to increased adoption, while surgical biopsy remains a smaller component of the market, primarily chosen for specific, complicated cases requiring surgical intervention. In recent years, the surgical biopsy segment has been identified as the fastest-growing due to advancements in surgical techniques and increased awareness of kidney diseases. Factors such as the evolving healthcare landscape, growing prevalence of kidney-related ailments, and technological innovations in surgical procedures are driving its growth, positioning it as a significant player in the overall market dynamics. Biopsy Method: Percutaneous Biopsy (Dominant) vs. Surgical Biopsy (Emerging) Percutaneous biopsy is recognized as the dominant method in the US kidney biopsy market, favored for its minimal invasiveness and effectiveness in diagnostics, allowing for rapid recovery and lower risks associated with complications. Healthcare providers increasingly prefer this method due to its cost-effectiveness and shorter procedure times. In contrast, surgical biopsy is emerging as a preferred option for challenging cases where percutaneous methods may not provide sufficient information. Although its share is smaller compared to percutaneous biopsy, surgical biopsy is gaining traction driven by advancements in surgical techniques and the growing demand for precise diagnostic solutions within the healthcare system. ## Competitive Benchmarking The kidney biopsy market exhibits a dynamic competitive landscape characterized by innovation and strategic partnerships among key players. Major companies such as Fresenius Medical Care (DE), Baxter International (US), and Thermo Fisher Scientific (US) are actively shaping the market through their operational focuses. Fresenius Medical Care (DE) emphasizes enhancing patient outcomes through advanced diagnostic technologies, while Baxter International (US) is concentrating on expanding its product portfolio to include minimally invasive biopsy solutions. Thermo Fisher Scientific (US) appears to be leveraging its expertise in molecular diagnostics to develop innovative biopsy techniques, thereby positioning itself as a leader in precision medicine. Collectively, these strategies contribute to a competitive environment that prioritizes technological advancement and patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several players vying for market share. This fragmentation allows for diverse offerings, yet the collective influence of major companies like Abbott Laboratories (US) and Siemens Healthineers (DE) is significant, as they drive trends in product development and market expansion. In October Abbott Laboratories (US) announced the launch of a new biopsy device designed to improve the accuracy of kidney tissue sampling. This strategic move is likely to enhance Abbott's competitive positioning by addressing the growing demand for precision in diagnostic procedures. The introduction of this device not only reflects Abbott's commitment to innovation but also aligns with the broader trend of integrating advanced technologies into medical devices, potentially setting new standards in the market. In September Siemens Healthineers (DE) expanded its partnership with a leading healthcare provider to enhance the integration of AI in kidney biopsy procedures. This collaboration aims to streamline workflows and improve diagnostic accuracy. The strategic importance of this partnership lies in Siemens' ability to leverage AI technologies, which could significantly enhance the efficiency of biopsy procedures and improve patient outcomes, thereby reinforcing its market position. In August Thermo Fisher Scientific (US) acquired a small biotech firm specializing in kidney diagnostics. This acquisition is indicative of Thermo Fisher's strategy to bolster its capabilities in the kidney biopsy segment. By integrating innovative technologies from the acquired firm, Thermo Fisher may enhance its product offerings and expand its market reach, further solidifying its role as a key player in the industry. As of November current competitive trends in the kidney biopsy market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances among companies are shaping the landscape, fostering innovation and enhancing operational efficiencies. Looking ahead, it is anticipated that competitive differentiation will evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This evolution suggests that companies that prioritize these aspects will likely gain a competitive edge in the market. ## Recent News & Developments Recent developments in the US Kidney Biopsy Market reflect significant advancements and competitive dynamics among key players. Companies like Exact Sciences, Hologic, and BioRad Laboratories are actively innovating within this space, focusing on novel biomarker discovery and enhanced diagnostic techniques. The market continues to see a growing interest in minimally invasive procedures, significantly benefitting patients and healthcare providers alike. In terms of mergers and acquisitions, there has been notable activity, including Roche Diagnostics acquiring a strategic technology firm in September 2023 to bolster their diagnostic offerings in kidney-related diseases, and Laboratory Corporation of America acquiring a promising biotechnology startup in August 2023 to enhance laboratory capabilities. Over the past few years, the US Kidney Biopsy Market has also experienced increased investment, fueled by a rise in chronic kidney diseases, heightening demand for groundbreaking diagnostic solutions. Companies such as Thermo Fisher Scientific and Quest Diagnostics are expanding their portfolio to include advanced genomic analysis technologies, further driving market growth. Overall, the US Kidney Biopsy Market showcases robust activity and innovation, positioning itself for significant future developments in the healthcare industry. ## Report Scope | MARKET SIZE 2024 | 693.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 724.67(USD Million) | | MARKET SIZE 2035 | 1133.19(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.57% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Fresenius Medical Care (DE), Baxter International (US), Thermo Fisher Scientific (US), Abbott Laboratories (US), Siemens Healthineers (DE), Roche Diagnostics (CH), Philips Healthcare (NL), Medtronic (US) | | Segments Covered | End-User, Indication, Type | | Key Market Opportunities | Advancements in minimally invasive techniques enhance patient outcomes in the kidney biopsy market. | | Key Market Dynamics | Technological advancements in kidney biopsy techniques enhance diagnostic accuracy and drive market growth in the US. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US kidney biopsy market in 2024?** A: The market valuation of the US kidney biopsy market was $693.0 Million in 2024. **Q: What is the projected market valuation for the US kidney biopsy market in 2035?** A: The projected market valuation for the US kidney biopsy market is $1133.19 Million in 2035. **Q: What is the expected CAGR for the US kidney biopsy market during the forecast period 2025 - 2035?** A: The expected CAGR for the US kidney biopsy market during the forecast period 2025 - 2035 is 4.57%. **Q: Which companies are considered key players in the US kidney biopsy market?** A: Key players in the US kidney biopsy market include Fresenius Medical Care, Baxter International, Thermo Fisher Scientific, Abbott Laboratories, Siemens Healthineers, Roche Diagnostics, Philips Healthcare, and Medtronic. **Q: What segment had the highest valuation in the US kidney biopsy market in 2024?** A: In 2024, the segment with the highest valuation was 'Hospitals & Clinics' at $480.0 Million. **Q: What are the projected valuations for the 'Kidney Failure' indication segment by 2035?** A: The projected valuation for the 'Kidney Failure' indication segment is $320.0 Million by 2035. **Q: How does the valuation of 'Percutaneous Biopsy' compare to 'Surgical Biopsy' in 2024?** A: In 2024, the valuation of 'Percutaneous Biopsy' was $670.0 Million, significantly higher than the $463.19 Million for 'Surgical Biopsy'. **Q: What is the projected growth for the 'Urology Centers' segment from 2024 to 2035?** A: The projected growth for the 'Urology Centers' segment is from $240.0 Million in 2024 to an anticipated higher valuation by 2035. **Q: What is the valuation range for the 'Proteinuria' indication segment in 2024?** A: The valuation range for the 'Proteinuria' indication segment in 2024 was between $163.0 Million and $283.19 Million. **Q: What is the expected trend for the US kidney biopsy market from 2025 to 2035?** A: The US kidney biopsy market is expected to experience steady growth from 2025 to 2035, driven by advancements in technology and increasing demand. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-kidney-biopsy-market-19402*